Predicine and Merck KGaA partner to highlight the importance of multi-parametric profiling of ctDNA and cfRNA for holistic molecular insight for detecting driver mutation, monitoring disease burden and drug resistance in advanced stage colorectal cancer.
Predicine, a molecular insights company headquartered in Hayward, California, with global footprints in China, today announced a clinical collaborative study with Merck KGaA, Darmstadt, Germany, a precision medicine driven company, which operates its biopharmaceuticals business in the U.S. and Canada as EMD Serono. Predicine and Merck KGaA will jointly present a study demonstrating the clinical utility of Predicine’s proprietary liquid biopsy platform for detection of genetic alterations using plasma-derived circulated tumor DNA (ctDNA) and cell-free RNA (cfRNA) in patients with advanced colorectal cancer (CRC) at the AACR-Advances in Liquid Biopsies Conference, taking place from January 13 to 16, 2020 in Miami, Florida.
Highlights of this study include:
- The clinical feasibility of simultaneous multiparametric profiling using a combined cfDNA and cfRNA liquid biopsy approach for molecular characterization in advance CRC.
- cfDNA-based detection of tumor mutation burden (TMB) and DNA damage repair pathway alterations.
- cfRNA-derived variant detection confirms the variants originally detected in cfDNA test and validates the high specificity results for report interpretation.
Data to be presented also support the importance of clinical implementation of a combined cfDNA and cfRNA test that could provide holistic molecular insight for detecting cancer driver mutations, monitoring efficacy/disease burden, as well as identifying sub-clonal alterations that may be relevant to drug resistance and tumor heterogeneity. Further investigation of the concordance between temporally matched tissue and liquid biopsy samples is ongoing.
“Liquid biopsy plays critical roles in advancing revolutionizing personalized cancer treatments and clinical drug development,” said Dr. Shidong Jia, Founder and CEO at Predicine. “Predicine’s next-generation sequencing-based comprehensive non-invasive liquid biopsy platform is the essential component for enabling biomarker-driven patient selection & enrollment, longitudinal disease monitoring and exploring the new paradigm for both targeted and combination therapies.
Predicine is a molecular insights company that is committed to advancing biomarker-driven precision medicine. Predicine has developed a breakthrough RNA- and DNA-based liquid biopsy technology for non-invasive cancer profiling, disease monitoring and assessing minimal residual disease. Through its CLIA and/or CAP facilities in the US and China, Predicine partners with leading biopharma companies and hospitals to support global clinical trials and personalized cancer therapy.